8. Immunomodulators and antineoplastics
8.2. Antineoplastics and supportive medicines
8.2.1. Cytotoxic medicines

---

### Cytarabine

**Indication**
Burkitt lymphoma including Burkitt leukaemia

**INN**
Cytarabine

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > unspecified: 100 mg in vial powder for injection

**EML status history**
First added in 1979 (TRS 641)
Changed in 2011 (TRS 965)
Changed in 2015 (TRS 994)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Cytarabine

**DrugBank**
Cytarabine

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for cytarabine on the complementary list of the EML and EMLc for use in treatment protocols for Burkitt lymphoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Burkitt lymphoma is attached.